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Abstract
Medication adherence studies increasingly collect data electronically, often using Medication
Event Monitoring System (MEMS) caps. Analyses typically focus on summary adherence
measures, although more complete analyses are possible using adaptive statistical methods. These
methods were used to describe individual-subject adherence patterns for MEMS data from a
clinical trial. Subjects were adaptively clustered into groups with similar adherence patterns and
clusters were compared on a variety of subject characteristics. There were seven different
adherence clusters: consistently high, consistently moderately high, consistently moderate,
consistently moderately low, consistently low, deteriorating starting early, and deteriorating late.
Compared to other subjects, subjects with consistently high and consistently moderately high
adherence were more likely to be male, White, and older and to maintain during study
participation a CD4 cell count over 500 and an HIV viral load of at most 400 copies/ml. These
results demonstrate the effectiveness of adaptive methods for comprehensive analysis of MEMS
data.
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Introduction
Medication adherence studies increasingly collect data electronically, often using
Medication Event Monitoring System (MEMS) caps (AARDEX, Zurich, Switzerland). An
advantage of electronic monitoring is that each subject's adherence can be analyzed
separately. Analyses typically focus on summary measures of individual-subject adherence,
e.g., percent prescribed doses taken (PDT), percent PDT at correct time interval, and
therapeutic coverage (Sereika and Dunbar-Jacobs, 2001). Percent PDT is used most
commonly, sometimes by itself (Holzemer et al., 2006), but often with other summary
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measures as well (Fletcher et al., 2005; Liu et al., 2006; Vrijens et al., 2005). Several studies
have used MEMS-derived summary measures to demonstrate that moderate levels of
adherence can result in virologic suppression with newer potent antiretroviral (ARV)
regimens (Bangsberg, 2006; Shuter et al., 2007). MEMS data have also been useful for
clarifying the possible relationship between viral load blips (i.e., intermittent low levels of
plasma HIV-1 RNA) and ARV adherence (Podsadecki et al., 2007).
As an alternative to summary measures, adaptive statistical methods can be used to visualize
individual-subject MEMS data grouped into cap opening counts and rates over separate time
periods and to describe associated individual-subject adherence patterns (Knafl et al., 2004).
Subjects can also be adaptively clustered into groups with similar adherence patterns
(Delucchi et al., 2006) rather than using simple adherence ranges (e.g., designating
adherence over 95% as high). In this paper, we used these adaptive methods to characterize
MEMS-based patterns of ARV adherence for HIV-positive participants of a randomized
clinical trial that evaluated the efficacy of a behavioral intervention to improve medication
adherence (Williams et al., 2006).
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Adaptive statistical methods are relatively new. Knafl et al. (2004) developed them
specifically to model individual-subject MEMS adherence data using Poisson regression,
commonly used with count/rate data, but they apply more generally (e.g. to linear and
logistic regression). Knafl, Fennie, and OMalley (2006) extended these methods to handle
repeated measurements and used them to model self-reported adherence over time.
In the context of MEMS data, these methods generate individual-subject adherence patterns
corresponding to estimates of mean adherence as an arbitrary function of time. Mean
adherence is treated as a general, possibly nonlinear function of time rather than as constant
in time as is implicit for standard summary adherence measures, and so reflects a subject's
actual adherence. Estimates are based on fractional polynomial models (Royston & Altman,
1994) in time. In other words, they are based on one or more transforms of time raised to
possibly fractional powers rather than to only integer powers as in standard polynomials.
The specific powers used in the model are selected through a heuristic search process
(defined in Knafl et al., 2004) applied to individual-subject MEMS data, and so adapted to
those data.

NIH-PA Author Manuscript

As part of the search process, models are evaluated using likelihood cross-validation (LCV)
scores with larger values indicating better models (Knafl et al., 2004; Stone 1977). The
advantage of LCV is that it adapts model evaluation to the distribution underlying an
analysis. Knafl et al. (2004) used it with the Poisson distribution to model MEMS
adherence. Delucchi et al. (2006) used it with mixtures of unstructured multivariate normal
distributions (Symons, 1981) to compare the results of clustering algorithms applied to
MEMS adherence patterns. Knafl, Fennie, & O'Malley (2006) used it with compound
symmetric multivariate normal distributions to evaluate models for repeated measurements.
Knafl and Grey (2007) used it with factor-analytic multivariate normal distributions to
evaluate exploratory and confirmatory factor analysis models.
Our earlier work has focused on the development of adaptive statistical methods, reporting
only limited analyses as examples of results possible for those developed methods. This
paper demonstrates instead the effectiveness of previously developed adaptive methods for
conducting comprehensive analyses of MEMS adherence data, the results of which are of
importance in their own right in identifying ARV adherence pattern types and describing
their relationships with subject characteristics and clinical outcomes.
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Methods
The ATHENA Project

NIH-PA Author Manuscript

The Adherence through Home Education and Nursing Assessment (ATHENA) Project was
a randomized clinical trial that tested a home-based nursing intervention to improve
adherence to ARV medications (Williams et al., 2006). Subjects were recruited from HIV
outpatient clinics and through flyers distributed at AIDS service organizations, support
groups, and community centers. HIV-infected men and women were eligible for the study if
they had been prescribed at least three ARV medications, spoke English or Spanish, had a
home or place to receive the intervention and were not participating in another adherence
study.
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ATHENA subjects were given pill bottles equipped with MEMS caps containing an ARV
medication randomly selected from among those prescribed at 2 doses per day. MEMS caps
recorded the date and time of each cap opening and presumably of medication-taking.
Subjects were informed about the purpose of the MEMS cap and were given verbal and
written instructions on its use. All subjects had a 4-week lead-in time to use the MEMS cap
before the baseline assessment. Face-to-face interview data, including self-reported
adherence to all HIV medications, were also collected at baseline and up to 6 other times at
3 month intervals by trained interviewers blinded to the group assignment. Self-reported
adherence was measured at each interview as the percent of prescribed ARV medications
reported to have been taken over the three days prior to an interview. CD4 cell counts and
HIV viral loads were obtained from subjects' medical records and matched in time to
interview dates. Data were collected from 1999 through 2002. MEMS cap data were
uploaded to the database at each study visit but were not reviewed with individual subjects.
Subjects received $25 per study visit and an additional $10 if they brought the MEMS cap to
the study visit. Subjects were also interviewed at 12 months on their experience with using
MEMS caps (Bova et al., 2005).
Modeling of Individual-Subject Adherence Data
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MEMS cap openings were grouped to generate opening counts and rates for disjoint
intervals of subject participation in the study. Intervals over which subjects were not
responsible for medication taking were removed prior to analysis. These included periods
when subjects were off ARVs on provider order or continuing ARV therapy in a hospital,
in-patient drug treatment facility, mental health facility, prison, or shelter. Subjects were
asked to refill their pill bottles only after opening them to take a dose, so no adjustments
were made for refill openings. Subjects were also asked not to pocket dose, but some
subjects admitted pocket dosing in a special interview on their MEMS use (Bova et al.
2005). However, no adjustments were made for pocket dosing since there was no
information in the interview data on when this occurred. MEMS data were not available for
all eligible ATHENA subjects and so subjects with and without MEMS data were compared
on a variety of categorical characteristics using χ2 tests unless any expected cell counts were
less than 5 in which case Fisher's exact test (based on the statistic PFET estimating the
population table probability) was used instead.
Adaptive Poisson regression modeling methods were used to analyze grouped MEMS data
(Knafl et al., 2004). Poisson regression was used because that is an appropriate method for
modeling event counts and rates. Each individual subject's grouped data were modeled
separately, adaptively generating an estimated adherence pattern over time for that subject.
These adherence patterns were allowed to have arbitrary nonlinear dependence on time,
possibly quite different from the constant pattern at the prescribed rate. Adherence was also
summarized using a measure of how consistent a subject's estimated adherence pattern was
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with presumed adherence at the prescribed rate. These percent consistency scores were
compared to scores based on the standard summary measure of percent PDT and to average
self-reported adherence during study participation.
Subjects were then adaptively clustered into groups with similarly shaped adherence patterns
(Delucchi et al., 2006). Each subject's adherence pattern was represented by a vector of
estimates of the mean cap opening rate at 20 equally spaced times (i.e., at 5%, 10%, …,
100% of total time of study participation). Subjects within adherence clusters were
compared on a variety of categorical characteristics using χ2 or Fisher's exact tests as before
and also on the basis of summary statistics for percent consistency, percent PDT, and
average self-reported adherence.
Overview of Adaptive Modeling
As an example of the adaptive modeling process, consider a hypothetical subject who used a
single MEMS cap for 540 days or about 18 months of study participation. Suppose that the
subject opened the cap during this period a total of 540 times for an overall cap opening rate
of 1.00 per day. The corresponding standard summary measure of percent PDT equals 50%
(obtained by dividing the overall cap opening rate by the prescribed rate of 2 doses per day
and converting to a percentage). This suggests that the subject was adherent throughout
study participation at one-half the prescribed rate, but that need not be the case.

NIH-PA Author Manuscript
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A better assessment of how consistent this subject's adherence was can be obtained by
grouping cap openings to generate counts and rates over disjoint periods of cap use. To do
this, partition the 540 day participation period into 100 equal-sized intervals, so that each
interval has length 5.4 days and corresponds to 1% of the subject's participation period at
different points in time during that period. Then, count the number of openings in each
interval and divide by 5.4 to get the associated opening rate for the interval. Suppose the
results are as plotted in Figure 1. Time in days of study participation is plotted on the x-axis
and the cap opening rate on the y-axis. This plot clearly indicates that the subject's
adherence was close to the prescribed rate for about the first half of study participation, but
then dropped to zero adherence for a while and then increased to around 0.5 medications per
day for the rest of the time. A percent PDT of 50% provides a very misleading assessment of
this subject's adherence. At no time during the study was the subject adherent at that rate. If
actual adherence is incorrectly assessed in this way for too many subjects, adherence
intervention studies relying on those adherence assessments may fail to demonstrate the
efficacy of those interventions. When the medications of interest are ARV agents,
undetected erratic or inconsistent adherence may explain the persistence of detectable virus,
due to the development of ARV resistance. Thus, an accurate description of the actual
pattern of medication adherence is of clinical significance.
Assume further that the interview data indicated that the subject was in an in-patient drug
treatment facility during the period of no cap openings in the middle of study participation.
The data for that period do not reflect subject's actual adherence, and so are appropriately
removed, leaving a gap in the data. The adaptive modeling process can be applied to these
adjusted data generating the curve of Figure 2, representing the subject's adherence pattern
over time during study participation. Since the curve is based on a fractional polynomial, it
is possible to interpolate the adherence pattern to gaps in the data, representing estimated
adherence for those gaps consistent with the subject's adherence when in control of
medication-taking. Gaps can also occur because of lost caps and are handled in the same
way.
The curve of Figure 2 is generated through a search process that starts from the constant
(intercept-only) model, systematically adds fractional power transforms of time to the
AIDS Behav. Author manuscript; available in PMC 2011 August 12.
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model, and then contracts the model removing any extraneous transforms and adjusting the
remaining transforms to improve the model. Models considered at the various stages of this
selection process are compared using LCV scores, with larger scores indicating better
models.
LCV scores can be used to obtain an alternative summary measure of how consistent
observed adherence is with prescribed adherence, reflecting the pattern in the data rather
than relying on an implicit assumption of a constant pattern. The LCV score for the model
generated by the adaptive process reflects the observed adherence pattern. An LCV score
can also be computed under the assumption that adherence was at the prescribed rate of 2
doses per day. When the observed adherence pattern is close to prescribed adherence, the
ratio of these two LCV scores expressed as percent will be close to 100%. The further the
observed adherence pattern is from prescribed adherence, the smaller this ratio will be.
Using this approach, the adherence pattern of Figure 2 is assessed as only 10.0% consistent
with the prescribed rate, much lower than the percent PDT score of 50%. For this subject,
the standard summary measure percent PDT provides an inflated assessment of adherence in
comparison to percent consistency.

NIH-PA Author Manuscript

We analyzed the MEMS adherence data for each subject one at a time in this way,
generating individual-subject adherence patterns and percent consistency scores. Since these
patterns span participation periods of different lengths, we matched them at relative times.
For each subject, we computed the 20-vector of estimates of mean adherence at 5%, 10%,
…, 100% of the subject's participation period. For example, for the hypothetical data of
Figure 2, we would use estimated adherence rates at 27, 54, 81, …, 540 days. For a subject
with a 480 day observation period, we would use estimated adherence rates at 24, 48, 72, …,
480 days instead. These two subjects would be assigned to the same cluster if their
adherence was similar at corresponding proportional times into their observation periods
(i.e., at multiples of 27 and 24 days, respectively). We clustered these 20-vectors into groups
of subjects with similar adherence patterns. We considered 16 different clustering
procedures (SAS Institute Inc., 2004), including 1- and 2-stage nearest neighbor procedures
as well as the average, centroid, complete, EML, flexible, k-means, McQuitty, median,
single, and Ward procedures, using for the average, centroid, median, and Ward procedures
either Euclidean distance or the default of squared Euclidean distance, and each of these
procedures with from 1 to 10 clusters. As described by Symons (1981), the mean vectors for
the associated multivariate normal mixture model represent the clusters and so would always
be treated as different across clusters while the covariance matrices may or may not be
treated as different. We treated variance vectors as different across clusters, but used a
common correlation matrix for all clusters in order to limit the number of parameters for the
mixture model. We compared these clustering alternatives using LCV scores with
likelihoods based on multivariate normal mixture models and then chose the alternative that
generated the best LCV score.
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Results
Characteristics of ATHENA Subjects
There were 172 eligible ATHENA subjects. Table I reports summary statistics for
continuous characteristics for these subjects. ATHENA subjects represent wide ranges of
HIV-positive patients as measured by these characteristics. Study participation ranged from
29 to 729 days with median of 476 days. Average self-reported adherence during study
participation ranged from 13.3% to 100.0% with median of 97.4%. Age at baseline ranged
from 22.3 to 63.2 years with median of 41.6 years. HIV duration at baseline ranged from 0.0
to 16.7 years with median of 8.1 years. Time on ARVs at baseline ranged from 0.0 to 15.2
years with median of 5.2 years. The minimum CD4 cell count during subjects' study
AIDS Behav. Author manuscript; available in PMC 2011 August 12.
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participation ranged from 3 to 1,481 with median of 296. The maximum HIV viral load
during subjects' study participation ranged from 20 to 850,000 copies/ml with median of
4,360 copies/ml. Undetectable HIV viral loads were set to associated detectable levels,
which started at 400 copies/ml at the beginning of the study and decreased to 50 copies/ml
during the study, with several detectable values recorded as less than 50 copies/ml. Means
and standard deviations are not reported in Table I because distributions for some of the
variables were distinctly skewed (e.g., the mean for the minimum CD4 cell count was 346
compared to a median of 296).
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Table II reports on a variety of categorical characteristics for ATHENA subjects. Of the 172
eligible subjects, 11.6% dropped out (due to death, withdrawal, or loss to follow-up), 50.6%
were randomized to the intervention group, 51.7% were male, 42.1% White, 18.7% Latino,
47.7% over 42.0 years old, 65.7% educated with a high school degree or less, 75.6%
participated for over 365 days, and 45.0% had an average self-reported adherence of 100%.
At some time during their study participation, 14.5% of the subjects were off ARVs on
provider order, 23.3% were in the hospital, 7.6% in an inpatient drug treatment facility,
1.7% in a mental health facility, 4.7% in prison, and 2.9% in a shelter. Subjects used from
1-3 MEMS caps during study participation, for a total of 200 caps, with 14.5% of the
subjects using more than 1 cap and 1.7% using 3 caps. The ARV controlled by the MEMS
cap at baseline was a nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) for 64.0%
of the subjects, a non-NRTI (NNRTI) for 11.6% of the subjects, a protease inhibitor (PI) for
23.3% of the subjects, and hydroxyurea for 1.2% of the subjects. With regard to HIV
disease, 49.7% had been HIV-positive for 8.0 years or less, 44.5% on ARVs for 5.0 years or
less, 21.6% had a minimum CD4 cell count of over 500 during study participation, and
29.2% had a maximum HIV viral load of 400 copies/ml or less during study participation.
Subjects with and without MEMS Data
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MEMS data were available for 161 (93.6%) of the eligible subjects from 187 (93.5%) of the
caps. These consisted of over 75,000 cap openings for over 66,000 days of use within a
period of about two and a half years from August, 1999 to March, 2002. Table II contains
results of comparisons of subjects with and without MEMS data. For subjects with MEMS
data, the ARV controlled by the MEMS cap changed for 11.2%, including 2 times for 0.6%,
and 1 time otherwise. The type of ARV controlled by the MEMS cap (NRTI, NNRTI, PI, or
hydroxyurea) changed for 5.6% of the subjects with MEMS data. No changes in ARVs were
recorded for subjects without MEMS data. Subjects without MEMS data were significantly
more likely than subjects with MEMS data to have dropped out (45.5% versus 8.7%; PFET
< .01, P < 0.01), been Latino (45.5% versus 16.9%; PFET = .03, P < 0.05), and been in an
inpatient drug treatment facility (27.3% versus 6.2%; PFET = .03, P < 0.05) as well as
significantly less likely to have participated for over 365 days (27.3% versus 78.9%; PFET
< .01, P < 0.01), but did not differ significantly on all the other characteristics of Table II.
Individual-Subject Adherence Patterns
Adherence for Subject 1 is plotted in Figure 3 and was clearly consistently close to the
prescribed rate of 2 doses per day throughout Subject 1's participation period. Not
surprisingly, Subject 1's adherence pattern over time during study participation was a
constant curve with value close to the prescribed rate and with associated percent
consistency score of 100%. However, not all subjects were as highly adherent as Subject 1.
Subject 2 had moderately high adherence (Figure 4), 88.8% consistent with prescribed
adherence that decreased from about the prescribed rate at baseline and then settled into a
nearly constant pattern somewhat below the prescribed rate. Subject 3 had moderate
adherence (Figure 5), 72.0% consistent with prescribed adherence that decreased quickly
from about the prescribed rate at baseline to a level around 1.5 openings per day and then
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eventually increased back to about the prescribed rate by the end of study participation.
While 72.0% is a moderately high level of adherence, it would usually not be considered
acceptable adherence for ARVs which require high levels to be effective (Low-Beer et al.,
2000; Paterson et al., 2000). Moreover, less than high levels of adherence may put a subject
at increased risk for developing drug resistant viral strains. Subject 4's adherence (Figure 6)
was moderately low at a constant rate just below one-half the prescribed rate and only
17.5% consistent with prescribed adherence. Subject 5 had low adherence (Figure 7), only
0.1% consistent with prescribed adherence, decreasing nonlinearly from about one-half the
prescribed rate at baseline to nearly zero adherence by the end of study participation.
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While the adherence patterns for Subjects 1-5 were not all constant, they were still relatively
consistent over time. Other subjects had distinctly deteriorating adherence patterns. For
example, Subject 6 had adherence (Figure 8) that was initially nearly constant at just below
the prescribed rate but that steadily deteriorated late in study participation to a very low
level. Subject 7's adherence (Figure 9) followed a distinctly nonlinear pattern over time,
deteriorating early from around the prescribed rate to essentially zero adherence and
remaining there for a long period at the end of study participation. Subject 7 was off
medications on provider order once during study participation, in prison once, and in an
inpatient drug treatment facility at three different times. MEMS data for these periods were
removed leaving the gaps in Subject 7's raw data. However, the adherence pattern was
interpolated across these gaps using the remaining MEMS data, providing an assessment of
the adherence Subject 7 would be expected to have had during these periods if Subject 7 had
been responsible for medication-taking.
Subject 7's actual adherence (as represented by the raw data of Figure 9) was between 1-2
openings per day for about the first half of study participation and then between 0-1
openings per day after that, producing an associated percent PDT of 45.4%. This suggests
that Subject 7 had mid-range adherence for most of study participation when in fact Subject
7 rarely had mid-range adherence during that time. On the other hand, Subject 7's adherence
pattern was only 0.5% consistent with prescribed adherence because that pattern is distinctly
different from a constant pattern around the prescribed rate. The standard summary measure
percent PDT inflates Subject 7's adherence in comparison to percent consistency. This also
demonstrates that results like those of the hypothetical example of Figures 1-2 can occur in
practice.
Distributions for Adherence Measures
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Individual-subject adherence patterns were generated for all 161 subjects with MEMS data.
The distribution for associated percent consistency scores (Figure 10) was bimodal with
peaks at low adherence levels of 10% consistency or less and at high adherence levels of
more than 90% consistency. Adherence was almost evenly spread out between these two
extremes with mid-range adherence the least likely level. On the other hand, percent PDT
(Figure 11) was similar to percent consistency for high levels of adherence of over 90%
PDT, perhaps because summary measures are likely to be close in value for high levels of
adherence. However, low levels of percent PDT of 10% or less rarely occurred. In between,
percent PDT was distinctly higher than percent consistency, an effect related to the inflation
of adherence for percent PDT identified for Subject 7. Self-reported adherence was available
for 171 of the eligible subjects at up to 7 time points. The distribution for average selfreported adherence over subject's study participation was highly skewed (Figure 12) with
67% of subjects self-reporting high levels of adherence over 90%. In comparison, only 25%
of subjects with MEMS data had high percent consistency over 90% and only 22% had high
percent PDT over 90%.
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When the individual-subject adherence patterns for all 161 subjects with MEMS data were
adaptively clustered, the best LCV score occurred for the Ward clustering procedure using
(unsquared) Euclidean distance and 7 clusters with 5 correponding to relatively consistent
patterns (Figure 13) and 2 others to distinctly deteriorating patterns (Figure 14). Clusters 1-5
represent consistent adherence types with, respectively, 35 (21.7%) of the subjects having
consistently high adherence, 23 (14.3%) consistently moderately high adherence, 22
(13.7%) consistently moderate adherence, 25 (15.5%) consistently moderately low
adherence, and 27 (16.8%) consistently low adherence. Clusters 6-7 represent deteriorating
adherence types with, respectively, 8 (5.0%) of the subjects having deteriorating late
adherence and 21 (13.0%) having deteriorating early adherence. The adherence patterns for
Subjects 1-7 were in Clusters 1-7, respectively, and so are representative of patterns within
the clusters. There were no sparse clusters with all containing patterns for at least 5% of the
subjects. Subjects tended to be allocated to clusters in comparable-sized sets with the
exception of the consistently high adherence cluster with the largest number of subjects and
the deteriorating late cluster with the smallest number of subjects. There was one other
clustering alternative that generated a competitive LCV score within 1% of the best score:
the reduced 4-cluster solution with the consistently moderately high and consistently
moderate clusters combined together, the consistently moderately low and the deteriorating
early and late clusters combined together, and the consistently high and consistently low
clusters uncombined. This reduced 4-cluster solution could have been used instead as a
parsimonious alternative to the 7-cluster solution.
Comparison of Adherence Types
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Since high levels of adherence are especially important for ARVs (Low-Beer et al., 2000;
Paterson et al., 2000), characterization of the consistently high and consistently moderately
high adherence levels of Clusters 1 and 2 in comparison to the combined moderate to low
adherence levels of Clusters 3-7 is of clinical relevance. Table III contains results for a
comparison of subjects across these three adherence types. Compared to subjects with
moderate to low adherence, subjects with consistently high adherence and consistently
moderately high adherence were significantly more likely to have been male (65.7% and
73.9%, respectively, versus 42.7%; χ2 = 10.62, df = 2, P < 0.01), White (71.4% and 52.2%,
respectively, versus 30.1%; χ2 = 19.38, df = 2, P < 0.01), older than 42.0 years (54.3% and
69.6%, respectively, versus 40.8%; χ2 = 6.99, df = 2, P < 0.05), have a minimum CD4 cell
count during study participation of over 500 (34.3% and 34.8%, respectively, versus 13.7%;
χ2 = 9.52, df = 2, P < 0.01), and a maximum HIV viral load during study participation of 400
copies/ml or less (62.9% and 47.8%, respectively, versus 15.7%; χ2 = 31.03, df = 2, P <
0.01). They were also significantly less likely to have the ARV controlled by the MEMS cap
change (5.7% and 0.0%, respectively, versus 15.5%; PFET <01, P < 0.05). On the other
hand, subjects with consistently high adherence and consistently moderately high adherence
had similar chances to subjects with moderate to low adherence of dropping out of the study,
being in the adherence intervention group, being Latino, being educated with a high school
degree or less, participating for over 365 days, ever being off ARVs on provider order, ever
being in a hospital, inpatient drug treatment facility, mental health facility, prison, or shelter,
having used multiple MEMS caps during study participation, having an NRTI, NNRTI, or
PI controlled by the MEMS cap at baseline, having the type of this ARV change during
study participation, being HIV-positive for 8.0 years or less, or being on ARVs for 5.0 years
or less. Also, when similar analyses were conducted comparing subjects of Clusters 3, 4, 5,
and 6-7 with consistently moderate, consistently moderately low, consistently low, and
deteriorating (i.e., deteriorating early and deteriorating late combined) adherence,
respectively, on the characteristics of Table III, all comparisons were statistically nonsignificant indicating that subjects in the moderate to low clusters were quite homogeneous.
AIDS Behav. Author manuscript; available in PMC 2011 August 12.
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Table IV presents summary statistics for percent consistency, percent PDT, and average
self-reported adherence for the consistently high, consistently moderately high, and
moderate to low adherence types. For the consistently high and consistently moderately high
adherence types, mean percent consistency was close to mean percent PDT and their
medians were close to their means, so that subjects within these two adherence types have
similar properties based on these summary adherence measures. However, there was a lot of
overlap between ranges of percent consistency and percent PDT scores for the three
adherence types (e.g., percent consistency scores can be as low as 78.4% for consistently
high adherence and as high as 96.4% for consistently moderately high adherence,
overlapping on an interval of length 18.0%), and so these adherence types cannot be simply
determined through the conventional use of ranges for summary adherence measures (e.g.,
over 95%). Similar results held for average self-reported adherence but with values for the
moderate to low adherence types much larger than for percent consistency and percent PDT.
Also, there were subjects with average self-reported adherence of 100% in the consistently
moderately high and moderate to low adherence types, not just the consistently high
adherence type.

Discussion
NIH-PA Author Manuscript

The present study provides an important contribution to the literature on ARV adherence. It
demonstrates that adaptive statistical methods provide a more comprehensive analysis of
adherence compared to the conventional use of summary measures like percent PDT and to
self-reported adherence. These methods provide for visualization of individual-subject
adherence patterns along with measures of how consistent those patterns are with presumed
adherence at the prescribed rate. Describing adherence data in this way may improve the
understanding of adherence for individual patients over time.
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These methods also provide characterizations of typical adherence patterns. Studies of other
chronic conditions have demonstrated the usefulness of identifying adherence pattern types
as an important first step towards developing tailored adherence interventions (Ahn et al.,
2008; Gerbino and Shoheiber, 2007; Russell et al., 2006). ARV adherence pattern types
could support the choice of regimens that match HIV-disease treatment strategies with
individual adherence behavior and guide behavioral interventions (Bangsberg, 2008). For
example, it would be possible to study whether certain lower cost interventions (e.g. pill
boxes, brief health care provider counseling) worked best in patients with more easily
remedied adherence patterns (e.g. late deteriorating) as opposed to costly, intensive
adherence interventions (e.g., medication managers, home-based nursing interventions)
which might work best for patients with consistently poor adherence.Tailored adherence
interventions coupled with better regimen choice could be an important advancement in
long-term ARV management.
Recognizing adherence types may be especially important as studies focus greater attention
on forgiveness of poor adherence (Shuter, 2008). The concept of forgiveness has been used
to describe the degree to which ARV dosing events can be missed and still maintain
adequate HIV viral suppression. Recent studies suggest that viral suppression is possible
with more modest adherence rates when contemporary regimens are used (e.g., boosted PI
or a potent NNRTI) (Bangsberg, 2006; Shuter et al., 2007). Therefore, it may be possible to
match adherence pattern types with regimen types having specific forgiveness profiles to
optimize individual regimen recommendations, e.g., patients with low adherence patterns
could be prescribed ARV regimens with high forgiveness profiles.
The deteriorating early and deteriorating late patterns may be of particular interest to
clinicians and researchers. It is important to note that both of these deteriorating adherence
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patterns began with suboptimal adherence and that subjects with deteriorating adherence
were not significantly different from the other moderate to low adherers on any major
characteristics. Qualitative methods may be needed to help uncover the hidden dimensions
related to deteriorating adherence compared to other types of moderate to low adherence.
Usable MEMS data were not available for all eligible ATHENA subjects. This is analogous
to non-response to a mailed questionnaire. The “non-response” rate in this case was quite
low (6.4% or 11/172 subjects), but the reported results may not apply generally if the nonresponders differed from responders on subject characteristics. Not surprisingly, ATHENA
subjects without MEMS data were more likely than subjects with MEMS data to have
dropped out of the study and to have been in an inpatient drug treatment facility during the
study as well as less likely to have participated longer in the study. However, they were also
more likely to be Latino. Consequently, reported results may not fully reflect adherence for
Latinos. On the other hand, there were no significant differences on a wide variety of other
subject characteristics, suggesting that the results may apply to a wide range of HIV-positive
subjects. In particular, subjects without MEMS data were not less likely to self-report having
high levels of adherence, suggesting that they were not more likely to be non-adherers.
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The MEMS data analyzed here were collected as part of an adherence intervention study.
While 60% of the subjects in the consistently high adherence group were also in the
intervention group compared to 43.5% of subjects in the consistently moderately high
adherence group and 48.5% in the moderate to low adherence group, these differences were
not statistically significant. When the consistently moderately high and moderate to low
groups were combined, the P-value improved but was still not significant. Larger sample
sizes may be needed to identify an effect to an intervention on having consistently high
adherence, and reported results could be used to power future studies.
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An earlier analysis (Williams et al., 2006) of ATHENA Project MEMS data identified an
intervention effect on the occurrence over time of high levels of adherence measured by a
percent PDT greater than 90%. However, this did not translate into a significant effect of the
intervention on improved CD4 cell counts and HIV viral loads. This earlier analysis
addressed whether or not intervention group subjects had a greater chance of high levels of
the summary measure percent PDT at any given time during their study participation. The
analyses reported here used different methods, addressed the different issue of whether
intervention group subjects had a greater chance of consistently high adherence throughout
their study participation, and found that such adherence was associated with improved levels
of CD4 cell counts and HIV viral loads. The results of these two kinds of analyses suggest
that measuring high adherence as a high value for a summary measure separately at each
point in time during a study may identify an intervention effect on adherence, but measuring
adherence as consistently high over time appears to be needed to also identify an
intervention effect on improved clinical outcomes like CD4 cell counts and HIV viral loads.
Consequently, interventions that effectively promote consistently high adherence over time
may result in better clinical outcomes.
A limitation of this study, and of MEMS caps in general, is that cap openings may overestimate adherence since caps can be opened without taking medications, for example, due
to refills. They may also under-estimate adherence, for example, due to pocket dosing. We
can only presume that the cap opening process provides a reasonably accurate assessment of
actual adherence. Another limitation of this study is the use of older ARV medications that
included higher pill burden and more frequent dosing than most contemporary regimens.
However, our analyses were conducted using only one ARV agent (taken twice daily),
which is similar to many current regimens. A more important problem is the inability to
calculate differential adherence among ARV agents used in combination. Gardner and
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colleagues (2008) found that differential adherence was present for 29% of subjects over a
60 month period and that differential adherence preceded virologic failure in 36% of
subjects. Therefore, further work is needed to examine differential adherence to newer
regimens using electronic monitoring and adaptive statistical methods.
The adherence pattern types identified here were for subjects of a single study. It is
important to replicate this work using data from other studies of adherence to ARVs as well
as to other kinds of medications. Other adherence pattern types may be identifiable, for
example, distinctly improving adherence types.
Adaptive statistical methods have only recently been developed and so are not supported as
standard options in popular statistical tools. To support their use, we have developed SAS
macros automating their computation. These macros are available from the corresponding
author.
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In summary, the use of adaptive statistical methods can identify variations in individualsubject adherence that are masked by summary adherence measures and by self-report. The
adherence types identified by these methods represent “signature adherence patterns”
(Bangsberg, 2008) characterizing patterns in adherence over time subjects are likely to have.
These adherence types may be important for predicting virologic failure and the
development of ARV resistance. Also, the availability of adherence types can support the
matching of subjects to adherence interventions tailored to their special needs.
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Figure 1. Hypothetical Grouped Adherence Data
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Figure 2. Hypothetical Adjusted Grouped Adherence Data with Adaptively Selected Curve
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Figure 3. High Adherence for Subject 1 100% Consistent with Prescribed Adherence
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Figure 4. Moderately High Adherence for Subject 2 88.8% Consistent with Prescribed
Adherence
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Figure 5. Moderate Adherence for Subject 3 72.0% Consistent with Prescribed Adherence
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Figure 6. Moderately Low Adherence for Subject 4 17.5% Consistent with Prescribed
Adherence
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Figure 7. Low Adherence for Subject 5 0.1% Consistent with Prescribed Adherence
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Figure 8. Deteriorating Late Adherence for Subject 6 48.2% Consistent with Prescribed
Adherence
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Figure 9. Deteriorating Early Adherence for Subject 7 0.5% Consistent with Prescribed
Adherence
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Figure 10. Distribution for Percent Consistency
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Figure 11. Distribution for Percent Prescribed Doses Taken (PDT)
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Figure 12. Distribution for Average Self-Reported Adherence
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Figure 13. Relatively Consistent Adherence Clusters

NIH-PA Author Manuscript
NIH-PA Author Manuscript
AIDS Behav. Author manuscript; available in PMC 2011 August 12.

Knafl et al.

Page 26

NIH-PA Author Manuscript
Figure 14. Distinctly Deteriorating Adherence Clusters
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172
172
171
167
164
171
171

age (years)

study participation (days)

average SRAb

HIV duration (years)

time on ARVs (years)

min CD4 cell countc

max HIV VL (copies/ml)d

20

3

0.0

0.0

13.0%

29

22.3

min

400

151

3.2

4.7

84.7%

389

36.9

25th

4,360

296

5.2

8.1

97.4%

476

41.6

50th

percentiles

57,100

477

9.0

11.3

100.0%

581

47.0

75th

850,000

1,481

15.2

16.7

100.0%

729

63.2

max

Maximum HIV viral load over up to 7 times at 3 month intervals during study participation. Undetectable viral loads were set to associated detectable limits of either 50 or 400 copies/ml.

d

c
Minimum CD4 cell count over up to 7 times at 3 month intervals during study participation.

The average over all available interviews of self-reported adherence to all antiretroviral medications for the three days prior to an interview.

Out of 172 eligible subjects.

b

a

ATHENA = Adherence through Home Education and Nursing Assessment; ARV = antiretroviral; VL = viral load; SRA = self-reported adherence

na

characteristic
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Table II

Comparison of ATHENA Subjects with and without MEMS Dataa
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characteristic

all subjects

with MEMS

without MEMS

% (n/total)

% (n/total)

% (n/total)

all subjects

93.6 (161/172)

6.4 (11/172)

dropoutb

11.6 (20/172)

8.7 (14/161)

54.5 (6/11)**

intervention group

50.6 (87/172)

50.3 (81/161)

54.5 (6/11)

male

51.7 (89/172)

52.2 (84/161)

45.5 (5/11)

White

42.1 (72/171)

42.5 (68/160)

36.4 (4/11)

Latino

18.7 (32/171)

16.9 (27/160)

45.5 (5/11)*

education ≤ HS degree

65.7 (113/172)

66.5 (107/161)

54.5 (6/11)

NIH-PA Author Manuscript

age > 42.0 years

47.7 (82/172)

47.8 (77/161)

45.5 (5/11)

participation > 365 days

75.6 (130/172)

78.9 (127/161)

27.3 (3/11)**

average SRA = 100.0%c

45.0 (77/171)

45.0 (72/160)

45.5 (5/11)

off ARVs on provider order

14.5 (25/172)

14.3 (23/161)

18.2 92/11)

hospitald

23.3 (40/172)

21.7 (35/161)

45.5 (5/11)

inpatient drug treatmentd

7.6 (13/172)

6.2 (10/161)

27.3 (3/11)*

mental health facilityd

1.7 (3/172)

1.9 (3/161)

0.0 (0/11)

prisond

4.7(8/172)

4.4 (7/161)

9.1 (1/11)

shelterd

2.9 (5/172)

2.5 (4/161)

9.1 (1/11)

multiple MEMS capse

14.5 (25/175)

14.3 (23/161)

18.2 (2/11)

NRTI for MEMSf

64.0 (110/172)

65.2 (105/161)

45.5 (5/11)

NNRTI for MEMSf

11.6 (20/172)

11.8 (19/161)

9.1 (1/11)

PI for MEMSf

23.3 (40/172)

22.4 (36/161)

36.4 (4/11)

ARV changed in MEMSf

11.2 (18/161)

type changed in MEMSf

5.6 (9/161)

NIH-PA Author Manuscript

HIV duration ≤ 8.0 years

49.7 (83/167)

48.7 (76/156)

63.6 (7/11)

time on ARVs ≤ 5.0 years

45.5 (73/164)

44.4 (68/153)

45.5 (5/11)

min CD4 > 500g

21.6 (37/171)

21.3 (34/160)

27.3 (3/11)

max VL ≤ 400 copies/mlh

29.2 (50/171)

30.6 (49/160)

9.1 (1/11)

ATHENA = Adherence through Home Education and Nursing Assessment; MEMS = Medication Event Monitoring System; HS = high school;
SRA = self-reported adherence; ARV = antiretroviral; NRTI = nucleoside/nucleotide reverse transcriptase inhibitor; NNRTI = non-NRTI; PI =
protease inhibitor; VL = viral load;
*

P< .05;

**

P < .01

a

Using a χ2 test for differences in occurrence with and without MEMS data, unless any expected cell counts were less than 5 in which case Fisher's
exact test with statistic PFET was used instead.
b

Of the 172 eligible subjects, 4 (2.3%) died, 4 (2.3%) withdrew, and 12 (7.0%) were lost to follow-up for a total of 20 (11.6%) dropouts. Of the 11
subjects without MEMS data, 0 (0.0%) died, 1 (9.1%) withdrew, and 5 (45.5%) were lost to follow-up for a total of 6 (54.5%) dropouts.
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c
The average over all available interviews of self-reported adherence to all antiretroviral medications for the three days prior to an interview.
d

Ever in the hospital, an inpatient drug treatment facility, a mental health facility, prison, or a shelter during study participation.
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e
Subjects used from 1-3 MEMS caps during study participation for a total of 200 caps. Data were available for analysis for 187 of the caps. Three
(1.7%) subjects used 3 caps, all with available data.
f
For 170 subjects, the pill bottle controlled by the MEMS cap contained at baseline either an NRTI, NNRTI, or PI. It contained hydroxyurea for the
other 2 (1.2%) subjects, 1 with and 1 without MEMS data. Information on changes to the ARV controlled by the MEMS cap was only available for
subjects with MEMS data. This ARV changed 2 times for 2 (1.2%) subjects, otherwise it changed at most 1 time.
g

Minimum CD4 cell count over up to 7 times at 3 month intervals during study participation.

h

Maximum HIV viral load over up to 7 times at 3 month intervals during study participation. Undetectable viral loads were set to associated
detectable limits of either 50 or 400 copies/ml.
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Comparison of ATHENA Subjects with MEMS Data by Type of Adherence
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characteristic

all subjects

type of adherence
consistently high

consistently moderately high

moderate to low

% (n/total)

% (n/total)

% (n/total)

21.7 (35/161)

14.3 (23/161)

64.0 (103/161)

dropoutb

11.4 (4/35)

4.4 (1/23)

8.7 (9/103)

intervention group

60.0 (21/35)

43.5 (10/23)

48.5 (50/103)

male

65.7 (23/35)

73.9 (17/23)

42.7 (44/103)**

White

71.4 (25/35)

52.2 (12/23)

30.1 (31/103)**

Latino

5.7 (2/35)

17.4 (4/23)

20.4 (21/103)

age > 42.0 years

54.3 (19/35)

69.6 (16/23)

40.8 (42/103)*

education ≤ HS degree

71.4 (25/35)

65.2 (15/23)

65.1 (67/103)

participation > 365 days

82.9 (29/35)

82.6 (19/23)

76.7 (79/103)
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off ARVs on provider order

8.6 (3/35)

1.9 (3/23)

16.5 (17/103)

hospitalc

17.1 (6/35)

30.4 (7/23)

21.4 (22/103)

inpatient drug treatmentc

2.9 (1/35)

4.4 (1/23)

7.8 (8/103)

mental health facilityc

0.0 (0/35)

0.0 (0/23)

2.9 (3/103)

prisonc

0.0 (0/35)

8.7 (2/23)

4.9 (5/103)

shelterc

2.9 (1/35)

4.4 (1/23)

1.9 (2/103)

multiple MEMS caps

14.5 (25/175)

14.3 (23/161)

18.2 (2/11)

NRTI in MEMSd

74.3 (26/35)

60.9 (14/23)

63.1 (65/103)

NNRTI in MEMSd

8.6 (3/35)

4.4 (1/23)

14.6 (15/103)

PI in MEMSd

17.1 (6/35)

34.8 (8/23)

21.4 (22/103)

ARV changed in MEMS

5.7 (2/35)

0.0 (0/23)

15.5 (16/103)**
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type changed in MEMS

2.9 (1/35)

0.0 (0/23)

7.8 (8/103)

HIV duration ≤ 8.0 years

47.1 (16/34)

47.8 (11/23)

49.5 (49/99)

time on ARVs ≤ 5.0 years

45.7 (16/35))

45.0 (9/20)

43.9 (43/98)

min CD4 > 500e

34.3 (12/35)

34.8 (8/23)

13.7 (14/102)*

max VL ≤ 400 copies/mlf

62.9 (22/35)

47.8 (11/23)

15.7 (16/102)**

ATHENA = Adherence through Home Education and Nursing Assessment; MEMS = Medication Event Monitoring System; HS = high school;
ARV = antiretroviral; NRTI = nucleoside/nucleotide reverse transcriptase inhibitor; NNRTI = non-NRTI; PI = protease inhibitor; VL = viral load;
*

P< .05;

**

P < .01

a

Using a χ2 test for differences in occurrence across adherence types, unless any expected cell counts were less than 5 in which case Fisher's exact
test was used instead.
b

Either died, withdrew, or lost to follow-up.

c
Ever in the hospital, an inpatient drug treatment facility, a mental health facility, prison, or a shelter during study participation.
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d

Based on the ARV controlled by the MEMS cap at baseline.

e
Minimum CD4 cell count over up to 7 times at 3 month intervals during study participation.

NIH-PA Author Manuscript

f
Maximum HIV viral load over up to 7 times at 3 month intervals during study participation. Undetectable viral loads were set to associated
detectable limits of either 50 or 400 copies/ml.
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Table IV

Summary Statistics for Adherence Measures by Type of Adherencea
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summary measure

type of adherence
consistently high

consistently moderately high

moderate to low

meanb

97.7%

84.1%

21.6%

median

97.1%

86.8%

10.1%

minimum

78.4%

59.4%

0.0%

maximum

100.0%

96.4%

89.0%

meanb

96.4%

85.0%

42.5%

median

97.1%

85.9%

42.2%

minimum

86.3%

76.9%

1.6%

maximum

100.0%

91.9%

83.8%

meanc

98.4%

96.3%

85.6%

median

100.0%

100.0%

90.8%

percent consistency

percent PDT

average self-reported adherence

NIH-PA Author Manuscript

minimum

87.0%

70.0%

25.0%

maximum

100.0%

100.0%

100.0%

PDT = percent doses taken
a

Percent consistency and percent PDT statistics computed for the 161 subjects with Medication Event Monitoring System (MEMS) data. Average
self-reported adherence computed for the 160 of these subjects with self-reported adherence data.
b

Significantly different by type of adherence at P < 0.01 for the F test of equal means with all three means distinctly different using Scheffé's
multiple comparisons procedure.
c
Significantly different by type of adherence at P < 0.01 for the F test of equal means with the mean for moderate to low adherence differing from
the means for high and moderately high adherence which did not differ from each other using Scheffé's multiple comparisons procedure.
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